Difference between revisions of "Paired box gene 8"

From Libre Pathology
Jump to navigation Jump to search
m (vauthors)
 
(15 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{ Infobox immunostain
{{ Infobox immunostain
| Name      = {{PAGENAME}}
| Name      = {{PAGENAME}}
| Image      =  
| Image      = Poorly differentiated carcinoma -- PAX8 - intermed mag.jpg
| Width      =
| Width      =
| Caption    =  
| Caption    = PAX8 staining in a poorly differentiated [[carcinoma]].
| Abbrev    = PAX8
| Abbrev    = PAX8
| Synonyms  =
| Synonyms  =
Line 10: Line 10:
| Use        = RCC versus other, gynecologic tract malignancy versus other
| Use        = RCC versus other, gynecologic tract malignancy versus other
| Subspecial = [[gynecologic pathology]], [[genitourinary pathology]]   
| Subspecial = [[gynecologic pathology]], [[genitourinary pathology]]   
| Pattern    =  
| Pattern    = nuclear stain
| Positive  = [[renal cell carcinoma]]s, [[renal oncocytoma]], thyroid tumours, [[serous carcinoma]], [[endometrial carcinoma]]s
| Positive  = [[renal cell carcinoma]]s, [[renal oncocytoma]], thyroid tumours, [[serous carcinoma]], [[endometrial carcinoma]]s
| Negative  =  
| Negative  =  
Line 24: Line 24:
*Nonserous epithelial [[ovarian tumours|ovarian neoplasms]] ~ 70%.<ref name=pmid21552115/>
*Nonserous epithelial [[ovarian tumours|ovarian neoplasms]] ~ 70%.<ref name=pmid21552115/>
*[[Endometrial carcinoma]]s ~ 98%.<ref name=pmid21552115/>
*[[Endometrial carcinoma]]s ~ 98%.<ref name=pmid21552115/>
*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal  | last1 = Sangoi | first1 = AR. | last2 = Ohgami | first2 = RS. | last3 = Pai | first3 = RK. | last4 = Beck | first4 = AH. | last5 = McKenney | first5 = JK. | last6 = Pai | first6 = RK. | title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. | journal = Mod Pathol | volume = 24 | issue = 3 | pages = 412-24 | month = Mar | year = 2011 | doi = 10.1038/modpathol.2010.176 | PMID = 20890270 }}</ref>
**Can help differentiate from lung NETs.
*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal |authors=Weissferdt A, Moran CA |title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis |journal=Am. J. Surg. Pathol. |volume=35 |issue=9 |pages=1305–10 |date=September 2011 |pmid=21836478 |doi=10.1097/PAS.0b013e3182260735 |url=}}</ref>
===May be positive===
*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal |authors=Chapel DB, Husain AN, Krausz T, McGregor SM |title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma |journal=Am. J. Surg. Pathol. |volume=41 |issue=12 |pages=1675–1682 |date=December 2017 |pmid=28877056 |doi=10.1097/PAS.0000000000000935 |url=}}</ref>).
==Negative staining==
[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg|thumb|right|300px|Negative PAX8 staining in a lymphoma.]]
*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal |authors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F |title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas |journal=Mod. Pathol. |volume=25 |issue=2 |pages=231–6 |date=February 2012 |pmid=22037256 |doi=10.1038/modpathol.2011.162 |url=}}</ref>
*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal  | last1 = Tacha | first1 = D. | last2 = Zhou | first2 = D. | last3 = Cheng | first3 = L. | title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. | journal = Appl Immunohistochem Mol Morphol | volume = 19 | issue = 4 | pages = 293-9 | month = Jul | year = 2011 | doi = 10.1097/PAI.0b013e3182025f66 | PMID = 21285870 }}</ref>
*Salivary gland and salivary gland tumours.<ref>{{cite journal |authors=Butler RT, Alderman MA, Thompson LD, McHugh JB |title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms |journal=Head Neck Pathol |volume=9 |issue=1 |pages=47–50 |date=March 2015 |pmid=24771139 |pmc=4382472 |doi=10.1007/s12105-014-0546-4 |url=}}</ref>


==See also==
==See also==

Latest revision as of 17:13, 25 March 2021

Paired box gene 8
Immunostain in short

PAX8 staining in a poorly differentiated carcinoma.
Abbreviation PAX8
Use RCC versus other, gynecologic tract malignancy versus other
Subspeciality gynecologic pathology, genitourinary pathology
Normal staining pattern nuclear stain
Positive renal cell carcinomas, renal oncocytoma, thyroid tumours, serous carcinoma, endometrial carcinomas

Paired box gene 8, commonly known by the abbreviation PAX8, is a commonly used immunostain in gynecologic pathology and genitourinary pathology.

Tumours with positive staining

May be positive

Negative staining

Negative PAX8 staining in a lymphoma.

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Laury, AR.; Perets, R.; Piao, H.; Krane, JF.; Barletta, JA.; French, C.; Chirieac, LR.; Lis, R. et al. (Jun 2011). "A comprehensive analysis of PAX8 expression in human epithelial tumors.". Am J Surg Pathol 35 (6): 816-26. doi:10.1097/PAS.0b013e318216c112. PMID 21552115.
  2. Sangoi, AR.; Ohgami, RS.; Pai, RK.; Beck, AH.; McKenney, JK.; Pai, RK. (Mar 2011). "PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.". Mod Pathol 24 (3): 412-24. doi:10.1038/modpathol.2010.176. PMID 20890270.
  3. Weissferdt A, Moran CA (September 2011). "Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis". Am. J. Surg. Pathol. 35 (9): 1305–10. doi:10.1097/PAS.0b013e3182260735. PMID 21836478.
  4. Chapel DB, Husain AN, Krausz T, McGregor SM (December 2017). "PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma". Am. J. Surg. Pathol. 41 (12): 1675–1682. doi:10.1097/PAS.0000000000000935. PMID 28877056.
  5. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F (February 2012). "N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas". Mod. Pathol. 25 (2): 231–6. doi:10.1038/modpathol.2011.162. PMID 22037256.
  6. Tacha, D.; Zhou, D.; Cheng, L. (Jul 2011). "Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.". Appl Immunohistochem Mol Morphol 19 (4): 293-9. doi:10.1097/PAI.0b013e3182025f66. PMID 21285870.
  7. Butler RT, Alderman MA, Thompson LD, McHugh JB (March 2015). "Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms". Head Neck Pathol 9 (1): 47–50. doi:10.1007/s12105-014-0546-4. PMC 4382472. PMID 24771139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382472/.